NASDAQ:VRTX

Vertex Pharmaceuticals - VRTX Stock Forecast, Price & News

$300.64

+3.21 (+1.08%)

(As of 10/4/2022 12:00 AM ET)

Add

Compare

Today's Range: $295.87
▼
$303.04
50-Day Range: $273.83
▼
$305.53
52-Week Range: $176.36
▼
$305.95

Volume: 1.54 million shs
Average Volume: 1.62 million shs
Market Capitalization: $77.10 billion

P/E Ratio: 24.30
Dividend Yield: N/A
Price Target: $291.65

Vertex Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.65 Rating Score
Upside/Downside: 3.0% Downside
$291.65 Price Target
Short Interest: Healthy
1.13% of Float Sold Short
Dividend Strength: N/A
Sustainability: -3.12
Upright™ Environmental Score
News Sentiment: 0.59
Based on 10 Articles This Week
Insider Trading: Selling Shares
$56.53 M Sold Last Quarter
Proj. Earnings Growth: 7.10%
From $12.67 to $13.57 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.28 out of 5 stars

Medical Sector

394th out of 1,087 stocks

Pharmaceutical Preparations Industry

176th out of 546 stocks

2.3

Analyst's Opinion

Consensus Rating
Vertex Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.65, and is based on 11 buy ratings, 6 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $291.65, Vertex Pharmaceuticals has a forecasted downside of 3.0% from its current price of $300.64.
Amount of Analyst Coverage
Vertex Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
1.13% of the float of Vertex Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Vertex Pharmaceuticals has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Vertex Pharmaceuticals has recently increased by 2.12%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Vertex Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Vertex Pharmaceuticals does not have a long track record of dividend growth.

3.3

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Vertex Pharmaceuticals has received a 37.41% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Cystic fibrosis medication" product. See details.
Environmental Sustainability
The Environmental Impact score for Vertex Pharmaceuticals is -3.12.

2.0

News and Social Media Coverage

News Sentiment
Vertex Pharmaceuticals has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.81 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 10 news articles for Vertex Pharmaceuticals this week, compared to 9 articles on an average week.
Search Interest
Only 32 people have searched for VRTX on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.
MarketBeat Follows
Only 27 people have added Vertex Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -16% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Vertex Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $56,532,979.00 in company stock.
Percentage Held by Insiders
Only 0.40% of the stock of Vertex Pharmaceuticals is held by insiders.
Percentage Held by Institutions
91.33% of the stock of Vertex Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

2.5

Earnings and Valuation

Earnings Growth
Earnings for Vertex Pharmaceuticals are expected to grow by 7.10% in the coming year, from $12.67 to $13.57 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Vertex Pharmaceuticals is 24.30, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 119.18.
Price to Earnings Ratio vs. Sector
The P/E ratio of Vertex Pharmaceuticals is 24.30, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 94.34.
Price to Earnings Growth Ratio
Vertex Pharmaceuticals has a PEG Ratio of 2.05. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Vertex Pharmaceuticals has a P/B Ratio of 7.57. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Vertex Pharmaceuticals (NASDAQ:VRTX) Stock

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Receive VRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vertex Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

VRTX Stock News Headlines

October 4, 2022 | sg.finance.yahoo.com

Here is What to Know Beyond Why Vertex Pharmaceuticals Incorporated (VRTX) is a Trending Stock

October 4, 2022 | seekingalpha.com

Vertex Pharmaceuticals: A Buy For Growth Potential

October 3, 2022 | ca.finance.yahoo.com

Investing in Vertex Pharmaceuticals (NASDAQ:VRTX) five years ago would have delivered you a 87% gain

October 1, 2022 | finance.yahoo.com

Vertex, Gene-Editing Leader, Heads 5 Resilient Stocks In Bear Market

September 29, 2022 | forbes.com

What’s Driving Vertex Pharmaceuticals Stock Higher?

September 28, 2022 | finance.yahoo.com

Vertex (VRTX), CRISPR to Seek FDA Nod for Hemoglobinopathy Therapy

September 28, 2022 | finance.yahoo.com

The 2 Best Stocks to Invest $5,000 in Right Now

September 27, 2022 | msn.com

Why CRISPR Therapeutics Stock Is Rising Today

September 27, 2022 | msn.com

Why Is Crispr Therapeutics (CRSP) Stock Up Today?

September 27, 2022 | finance.yahoo.com

CRISPR, Vertex say FDA granted rolling review to experimental CRISPR therapy

September 27, 2022 | finance.yahoo.com

Crispr Stock Jumps After Unveiling Timeline For FDA Submission Of First-Ever CRISPR Drug

September 26, 2022 | finance.yahoo.com

Dow Jones Continues To Fall As Stock Market Correction Worsens; Treasury Yields Surge

September 25, 2022 | finance.yahoo.com

Is Now the Right Time to Be Buying Growth Stocks?

September 25, 2022 | finance.yahoo.com

Those who invested in Vertex Pharmaceuticals (NASDAQ:VRTX) five years ago are up 86%

September 23, 2022 | finance.yahoo.com

Dow Jones Futures Sell Off Ahead Of Powell Comments As Recession Fears Mount

September 21, 2022 | finance.yahoo.com

Is Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) Stock's Recent Performance A Reflection Of Its Financial Health?

September 21, 2022 | finance.yahoo.com

Dow Jones Rises Ahead Of Fed Decision, Powell Comments

September 20, 2022 | finance.yahoo.com

Dow Jones Sells Off Ahead Of Fed Meeting; Treasury Yields Jump; Ford Dives 10% On Inflation Warning

September 19, 2022 | finance.yahoo.com

Dow Jones Falls As 10-Year Treasury Yield Surges Ahead Of Fed Meeting

September 19, 2022 | finance.yahoo.com

Dow Jones Futures Fall Ahead Of Fed Meeting As This Reality Sets In; Five Stocks Holding Up

September 18, 2022 | finance.yahoo.com

Dow Jones Futures Look To Fed Meeting But This Reality Has Set In; Five Stocks Holding Up

September 16, 2022 | seekingalpha.com

VRTX Vertex Pharmaceuticals Incorporated

September 16, 2022 | finance.yahoo.com

Vertex Pharmaceuticals Holds Steady In Stormy Market

September 15, 2022 | finance.yahoo.com

All the Stocks I'm Selling in This Wild Market

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive VRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vertex Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

VRTX Company Calendar

Last Earnings: 8/04/2022
Today: 10/04/2022
Next Earnings (Estimated): 11/01/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:VRTX
CUSIP: 92532F10
CIK: 875320
Web: www.vrtx.com
Phone: (617) 341-6100
Fax: 617-576-2109
Employees: 3,900
Year Founded: 1989

Price Target and Rating

Average Stock Price Forecast: $291.65
High Stock Price Forecast: $365.00
Low Stock Price Forecast: $222.00
Forecasted Upside/Downside: -3.0%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.65
Research Coverage: 17 Analysts

Profitability

EPS (Most Recent Fiscal Year): $12.37
Trailing P/E Ratio: 24.30
Forward P/E Ratio: 23.73
P/E Growth: 2.05
Net Income: $2.34 billion
Net Margins: 38.26%
Pretax Margin: 47.10%
Return on Equity: 31.22%
Return on Assets: 23.72%

Debt

Debt-to-Equity Ratio: 0.04
Current Ratio: 4.50
Quick Ratio: 4.36

Sales & Book Value

Annual Sales: $7.57 billion
Price / Sales: 10.18
Cash Flow: $13.12 per share
Price / Cash Flow: 22.92
Book Value: $39.72 per share
Price / Book: 7.57

Miscellaneous

Outstanding Shares: 256,459,000
Free Float: 255,433,000
Market Cap: $77.10 billion
Optionable: Optionable
Beta: 0.42

Social Links

Key Executives

Dr. Jeffrey Marc Leiden M.D. (Age 66)
Ph.D., Exec. Chairman
Comp: $281.98k

Dr. Reshma Kewalramani FASN (Age 49)
M.D., CEO, Pres & Director
Comp: $4.27M

Mr. Charles F. Wagner Jr. (Age 54)
Exec. VP & CFO
Comp: $1.85M

Mr. Stuart A. Arbuckle B.Sc. (Age 56)
Exec. VP & COO
Comp: $2.56M

Dr. Ourania Tatsis Ph.D. (Age 51)
Exec. VP and Chief Regulatory & Quality Officer
Comp: $1.33M

Ms. Kristen C. Ambrose (Age 45)
Chief Accounting Officer & SVP of Accounting, Tax, Treasury, Strategic Sourcing & Corp. Services

Dr. David M. Altshuler M.D. (Age 57)
Ph.D., Exec. VP of Global Research & Chief Scientific Officer

Mr. Mike Tirozzi
SVP and Chief Information & Data Officer

Mr. Michael Partridge
Sr. VP of Investor Relations

Mr. Damian W. Wilmot Esq. (Age 46)
Sr. VP, Chief Risk and Compliance Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

VRTX Stock - Frequently Asked Questions

Should I buy or sell Vertex Pharmaceuticals stock right now?: 17 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vertex Pharmaceuticals in the last year. There are currently 6 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VRTX shares.
View VRTX analyst ratings or view top-rated stocks.
What is Vertex Pharmaceuticals' stock price forecast for 2022?: 17 brokerages have issued 1-year target prices for Vertex Pharmaceuticals' stock. Their VRTX share price forecasts range from $222.00 to $365.00. On average, they predict the company's share price to reach $291.65 in the next year. This suggests that the stock has a possible downside of 2.7%.
View analysts price targets for VRTX or view top-rated stocks among Wall Street analysts.
How have VRTX shares performed in 2022?: Vertex Pharmaceuticals' stock was trading at $219.60 at the beginning of the year. Since then, VRTX stock has increased by 36.4% and is now trading at $299.64.
View the best growth stocks for 2022 here.
When is Vertex Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our VRTX earnings forecast.
How were Vertex Pharmaceuticals' earnings last quarter?: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) released its earnings results on Thursday, August, 4th. The pharmaceutical company reported $3.25 earnings per share for the quarter, beating analysts' consensus estimates of $3.05 by $0.20. The pharmaceutical company had revenue of $2.20 billion for the quarter, compared to analyst estimates of $2.13 billion. Vertex Pharmaceuticals had a net margin of 38.26% and a trailing twelve-month return on equity of 31.22%. The business's quarterly revenue was up 22.5% compared to the same quarter last year. During the same period in the prior year, the company earned $2.80 earnings per share.
Read the conference call transcript.
What guidance has Vertex Pharmaceuticals issued on next quarter's earnings?: Vertex Pharmaceuticals issued an update on its FY 2022 earnings guidance on Thursday, August, 25th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $8.60 billion-$8.80 billion, compared to the consensus revenue estimate of $8.58 billion.
What is Reshma Kewalramani's approval rating as Vertex Pharmaceuticals' CEO?: 31 employees have rated Vertex Pharmaceuticals Chief Executive Officer Reshma Kewalramani on Glassdoor.com. Reshma Kewalramani has an approval rating of 76% among the company's employees.

What other stocks do shareholders of Vertex Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Vertex Pharmaceuticals investors own include NVIDIA (NVDA), Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), Salesforce (CRM), Netflix (NFLX), Intel (INTC) and PayPal (PYPL).
What is Vertex Pharmaceuticals' stock symbol?: Vertex Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRTX."
Who are Vertex Pharmaceuticals' major shareholders?: Vertex Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Fulton Bank N.A. (0.00%), Symmetry Partners LLC (0.00%), Wedmont Private Capital (0.00%) and AdvisorNet Financial Inc (0.00%). Insiders that own company stock include Amit Sachdev, Bastiano Sanna, Bruce I Sachs, Charles F Wagner Jr, David Altshuler, Jeffrey M Leiden, Joy Liu, Kristen Ambrose, Margaret G Mcglynn, Michael Parini, Ourania Tatsis, Paul M Silva, Reshma Kewalramani, Sangeeta N Bhatia, Sangeeta N Bhatia, Stuart A Arbuckle, William D Young and Yuchun Lee.
View institutional ownership trends.
How do I buy shares of Vertex Pharmaceuticals?: Shares of VRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Vertex Pharmaceuticals' stock price today?: One share of VRTX stock can currently be purchased for approximately $299.64.
How much money does Vertex Pharmaceuticals make?: Vertex Pharmaceuticals (NASDAQ:VRTX) has a market capitalization of $76.85 billion and generates $7.57 billion in revenue each year. The pharmaceutical company earns $2.34 billion in net income (profit) each year or $12.37 on an earnings per share basis.
How many employees does Vertex Pharmaceuticals have?: The company employs 3,900 workers across the globe.
Does Vertex Pharmaceuticals have any subsidiaries?: The following companies are subsidiares of Vertex Pharmaceuticals: Aurora Biosciences Corporation, Exonics Therapeutics, Semma Therapeutics, The Vertex Foundation Inc., Torreyana Insurance Company Inc., Vectrus, Vertex Farmaceutica do Brasil LTDA, Vertex Holdings Inc., Vertex Pharmaceuticals (Australia) Pty. Ltd., Vertex Pharmaceuticals (CH) GmbH, Vertex Pharmaceuticals (Canada) Incorporated, Vertex Pharmaceuticals (Cayman 509) Limited, Vertex Pharmaceuticals (Cayman 765) Limited, Vertex Pharmaceuticals (Cayman 787) Limited, Vertex Pharmaceuticals (Cayman III) Limited, Vertex Pharmaceuticals (Cayman) Limited, Vertex Pharmaceuticals (Czech Republic) s.r.o, Vertex Pharmaceuticals (Delaware) LLC, Vertex Pharmaceuticals (Distribution) Incorporated, Vertex Pharmaceuticals (Europe) Limited, Vertex Pharmaceuticals (France) SAS, Vertex Pharmaceuticals (Germany) GmbH, Vertex Pharmaceuticals (Ireland) Limited, Vertex Pharmaceuticals (Italy) S.r.L., Vertex Pharmaceuticals (Netherlands) B.V., Vertex Pharmaceuticals (Poland) sp. z.o.o, Vertex Pharmaceuticals (Portugal), Vertex Pharmaceuticals (Puerto Rico) LLC, Vertex Pharmaceuticals (San Diego) LLC, Vertex Pharmaceuticals (Singapore) Pte. Ltd., Vertex Pharmaceuticals (Spain) S.L., Vertex Pharmaceuticals (Sweden) AB, Vertex Pharmaceuticals (U.K.) Limited, Vertex Pharmaceuticals GmbH, Vertex Pharmaceuticals Single Member Societe Anonyme, and Vertex Securities Corporation.
Read More
How can I contact Vertex Pharmaceuticals?: Vertex Pharmaceuticals' mailing address is 50 NORTHERN AVENUE, BOSTON MA, 02210. The official website for the company is www.vrtx.com. The pharmaceutical company can be reached via phone at (617) 341-6100, via email at investorinfo@vrtx.com, or via fax at 617-576-2109.

This page (NASDAQ:VRTX) was last updated on 10/4/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Vertex Pharmaceuticals - VRTX Stock Forecast, Price & News

Vertex Pharmaceuticals MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows